These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 7594671)
21. Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease. Kalish RA; Leong JM; Steere AC Infect Immun; 1995 Jun; 63(6):2228-35. PubMed ID: 7768602 [TBL] [Abstract][Full Text] [Related]
22. Growth-inhibiting antibody responses of humans vaccinated with recombinant outer surface protein A or infected with Borrelia burgdorferi or both. Luke CJ; Marshall MA; Zahradnik JM; Bybel M; Menefee BE; Barbour AG J Infect Dis; 2000 Mar; 181(3):1062-8. PubMed ID: 10720532 [TBL] [Abstract][Full Text] [Related]
23. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. Stover CK; Bansal GP; Hanson MS; Burlein JE; Palaszynski SR; Young JF; Koenig S; Young DB; Sadziene A; Barbour AG J Exp Med; 1993 Jul; 178(1):197-209. PubMed ID: 8315378 [TBL] [Abstract][Full Text] [Related]
24. The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: a Lyme disease vaccine. Wallich R; Kramer MD; Simon MM Infection; 1996; 24(5):396-7. PubMed ID: 8923055 [No Abstract] [Full Text] [Related]
25. Characterization of canine humoral immune responses to outer surface protein subunit vaccines and to natural infection by Lyme disease spirochetes. Ma J; Bulger PA; Dante S; Davis DR; Perilli-Palmer B; Coughlin RT J Infect Dis; 1995 Apr; 171(4):909-15. PubMed ID: 7706819 [TBL] [Abstract][Full Text] [Related]
26. Adjuvanted Lyme disease vaccine: a review of its use in the management of Lyme disease. Onrust SV; Goa KL Drugs; 2000 Feb; 59(2):281-99. PubMed ID: 10730551 [TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Wressnigg N; Pöllabauer EM; Aichinger G; Portsmouth D; Löw-Baselli A; Fritsch S; Livey I; Crowe BA; Schwendinger M; Brühl P; Pilz A; Dvorak T; Singer J; Firth C; Luft B; Schmitt B; Zeitlinger M; Müller M; Kollaritsch H; Paulke-Korinek M; Esen M; Kremsner PG; Ehrlich HJ; Barrett PN Lancet Infect Dis; 2013 Aug; 13(8):680-9. PubMed ID: 23665341 [TBL] [Abstract][Full Text] [Related]
28. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21. Coughlin RT; Fish D; Mather TN; Ma J; Pavia C; Bulger P J Infect Dis; 1995 Apr; 171(4):1049-52. PubMed ID: 7706788 [TBL] [Abstract][Full Text] [Related]
29. Vaccination as a modality to prevent Lyme disease. A status report. Wormser GP Infect Dis Clin North Am; 1999 Mar; 13(1):135-48, vii. PubMed ID: 10198796 [TBL] [Abstract][Full Text] [Related]
30. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. Luke CJ; Carner K; Liang X; Barbour AG J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201 [TBL] [Abstract][Full Text] [Related]
31. A new approach to a Lyme disease vaccine. Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174 [TBL] [Abstract][Full Text] [Related]
32. Killing of Borrelia burgdorferi by antibody elicited by OspA vaccine is inefficient in the absence of complement. Nowling JM; Philipp MT Infect Immun; 1999 Jan; 67(1):443-5. PubMed ID: 9864253 [TBL] [Abstract][Full Text] [Related]
33. Antibody responses of rats and humans to flagella-less cells and OspA protein of Borrelia burgdorferi. Sadziene A; Thompson PA; Barbour AG Ann N Y Acad Sci; 1996 Oct; 797():140-50. PubMed ID: 8993358 [No Abstract] [Full Text] [Related]
34. Immunization against Lyme disease--an important first step. Steigbigel RT; Benach JL N Engl J Med; 1998 Jul; 339(4):263-4. PubMed ID: 9673306 [No Abstract] [Full Text] [Related]
35. Activation of monocytes by three OspA vaccine candidates: lipoprotein OspA is a potent stimulator of monokines. Häupl T; Landgraf S; Netusil P; Biller N; Capiau C; Desmons P; Hauser P; Burmester GR FEMS Immunol Med Microbiol; 1997 Sep; 19(1):15-23. PubMed ID: 9322065 [TBL] [Abstract][Full Text] [Related]
36. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA. Eschner AK; Mugnai K Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386 [TBL] [Abstract][Full Text] [Related]
37. Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine. Ma J; Hine PM; Clough ER; Fish D; Coughlin RT; Beltz GA; Shew MG Vaccine; 1996 Oct; 14(14):1366-74. PubMed ID: 9004447 [TBL] [Abstract][Full Text] [Related]
38. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease. Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567 [TBL] [Abstract][Full Text] [Related]
39. Early and specific antibody response to OspA in Lyme Disease. Schutzer SE; Coyle PK; Dunn JJ; Luft BJ; Brunner M J Clin Invest; 1994 Jul; 94(1):454-7. PubMed ID: 8040289 [TBL] [Abstract][Full Text] [Related]
40. T helper cell priming of mice to Borrelia burgdorferi OspA leads to induction of protective antibodies following experimental but not tick-borne infection. Zhong W; Gern L; Kramer M; Wallich R; Simon MM Eur J Immunol; 1997 Nov; 27(11):2942-7. PubMed ID: 9394822 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]